MedKoo Biosciences

Nisoxetine
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584876

CAS#: 53179-07-0

Description: Nisoxetine is a potent inhibitor for norepinephrine uptake into rat brain synaptosomes and brain.

Chemical Structure

Nisoxetine

CAS# 53179-07-0

Instruction

Theoretical Analysis

MedKoo Cat#: 584876
Name: Nisoxetine
CAS#: 53179-07-0
Chemical Formula: C17H21NO2
Exact Mass: 271.16
Molecular Weight: 271.360
Elemental Analysis: C, 75.25; H, 7.80; N, 5.16; O, 11.79

Price and Availability

Size	Price	Availability
50mg	USD 450	2 Weeks
100mg	USD 750	2 Weeks
200mg	USD 1350	2 Weeks
500mg	USD 2850	2 Weeks
1g	USD 4350	2 Weeks
2g	USD 6950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Nisoxetine

IUPAC/Chemical Name: Benzenepropanamine, gamma-(2-methoxyphenoxy)-N-methyl-

InChi Key: ITJNARMNRKSWTA-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3

SMILES Code: CNCCC(OC1=CC=CC=C1OC)C2=CC=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 271.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Leung YM, Chu CC, Kuo CS, Chen YW, Wang JJ. Nisoxetine blocks sodium currents and elicits spinal anesthesia in rats. Pharmacol Rep. 2013;65(2):350-7. PubMed PMID: 23744419.

2: Leung YM, Chu CC, Kuo CS, Chen YW, Hung CH, Wang JJ. Isobolographic analysis of interaction between nisoxetine- and mepivacaine-induced spinal blockades in rats. Fundam Clin Pharmacol. 2014 Feb;28(1):88-94. doi: 10.1111/j.1472-8206.2012.01070.x. Epub 2012 Aug 14. PubMed PMID: 22889000.

3: Tejani-Butt SM. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther. 1992 Jan;260(1):427-36. PubMed PMID: 1731049.

4: Bello NT, Walters AL, Verpeut JL, Cunha PP. High-fat diet-induced alterations in the feeding suppression of low-dose nisoxetine, a selective norepinephrine reuptake inhibitor. J Obes. 2013;2013:457047. doi: 10.1155/2013/457047. Epub 2013 Jan 30. PubMed PMID: 23431425; PubMed Central PMCID: PMC3570928.

5: Bermingham DP, Hardaway JA, Snarrenberg CL, Robinson SB, Folkes OM, Salimando GJ, Jinnah H, Blakely RD. Acute blockade of the Caenorhabditis elegans dopamine transporter DAT-1 by the mammalian norepinephrine transporter inhibitor nisoxetine reveals the influence of genetic modifications of dopamine signaling in vivo. Neurochem Int. 2016 Sep;98:122-8. doi: 10.1016/j.neuint.2016.01.008. Epub 2016 Feb 3. PubMed PMID: 26850478; PubMed Central PMCID: PMC4969213.

6: Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ. [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70. PubMed PMID: 8684598.

7: Chen YW, Chu CC, Chen YC, Wang JJ, Hung CH, Shao DZ. Nisoxetine produces local but not systemic analgesia against cutaneous nociceptive stimuli in the rat. Eur J Pharmacol. 2012 Jan 30;675(1-3):22-5. doi: 10.1016/j.ejphar.2011.11.042. Epub 2011 Dec 7. PubMed PMID: 22166377.

8: Penmatsa A, Wang KH, Gouaux E. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol. 2015 Jun;22(6):506-508. doi: 10.1038/nsmb.3029. Epub 2015 May 11. PubMed PMID: 25961798; PubMed Central PMCID: PMC4608549.

9: Tejani-Butt SM, Ordway GA. Effect of age on [3H]nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans. Brain Res. 1992 Jun 26;583(1-2):312-5. PubMed PMID: 1504838.

10: Snoddy AM, Tessel RE. Nisoxetine and amphetamine share discriminative stimulus properties in mice. Pharmacol Biochem Behav. 1983 Aug;19(2):205-10. PubMed PMID: 6605539.

11: Bello NT, Yeh CY, Verpeut JL, Walters AL. Binge-like eating attenuates nisoxetine feeding suppression, stress activation, and brain norepinephrine activity. PLoS One. 2014 Apr 2;9(4):e93610. doi: 10.1371/journal.pone.0093610. eCollection 2014. PubMed PMID: 24695494; PubMed Central PMCID: PMC3973562.

12: Tejani-Butt SM, Brunswick DJ, Frazer A. [3H]nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol. 1990 Nov 27;191(2):239-43. PubMed PMID: 2086242.

13: Shearman LP, Meyer JS. Norepinephrine transporters in rat placenta labeled with [3H]nisoxetine. J Pharmacol Exp Ther. 1998 Feb;284(2):736-43. PubMed PMID: 9454822.

14: Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem. 1995 Jun;64(6):2792-800. PubMed PMID: 7760060.

15: Shang Y, Dluzen DE. Nisoxetine infusion into the olfactory bulb enhances the capacity for male rats to identify conspecifics. Neuroscience. 2001;104(4):957-64. PubMed PMID: 11457583.

16: Zhen J, Ali S, Dutta AK, Reith ME. Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive. J Neurosci Methods. 2012 Jan 15;203(1):19-27. doi: 10.1016/j.jneumeth.2011.08.044. Epub 2011 Sep 12. PubMed PMID: 21933682; PubMed Central PMCID: PMC3221803.

17: Borbély Z, Csomó BK, Kittel Á, Gerber G, Varga G, Vizi ES. Effect of rat spinal cord injury (hemisection) on the ex vivo uptake and release of [(3)H]noradrenaline from a slice preparation. Brain Res Bull. 2017 May;131:150-155. doi: 10.1016/j.brainresbull.2017.04.007. Epub 2017 Apr 20. PubMed PMID: 28434993.

18: Kung MP, Choi SR, Hou C, Zhuang ZP, Foulon C, Kung HF. Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol. 2004 Jul;31(5):533-41. PubMed PMID: 15219270.

19: Arime Y, Kasahara Y, Hall FS, Uhl GR, Sora I. Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice. Neuropsychopharmacology. 2012 Oct;37(11):2522-30. doi: 10.1038/npp.2012.114. Epub 2012 Jul 11. PubMed PMID: 22781838; PubMed Central PMCID: PMC3442347.

20: Lemberger L, Terman S, Rowe H, Billings R. The effect of nisoxetine (Lilly compound 94939), a potential antidepressant, on biogenic amine uptake in man. Br J Clin Pharmacol. 1976 Apr;3(2):215-20. PubMed PMID: 788744; PubMed Central PMCID: PMC1428886.

Your view history

Nisoxetine new featured